![Juliette Audet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 508 703 $ au 31/05/2026
Juliette Audet currently works at NewAmsterdam Pharma BV, as Non-Executive Director, Mestag Therapeutics Ltd., as Director, NewAmsterdam Pharma Holding BV, as Non-Executive Director from 2020, and NewAmsterdam Pharma Co. NV, as Chief Business Officer from 2024.
Ms. Audet also formerly worked at Annexon, Inc., as Director, TScan Therapeutics, Inc., as Director, Novartis Venture Funds (USA), as Senior Associate from 2018 to 2019, and Forbion Capital Partners Management Holding BV, as Partner from 2020 to 2024.
Ms. Audet received her undergraduate degree and graduate degree from École Polytechnique Fédérale de Lausanne and Masters Business Admin degree from Harvard Business School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/05/2025 | 15 104 ( 0,01 % ) | 508 703 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 01/04/2024 |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Directeur/Membre du Conseil | 01/01/2020 |
Mestag Therapeutics Ltd.
 Mestag Therapeutics Ltd. Financial ConglomeratesFinance Provides investment services | Directeur/Membre du Conseil | - |
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat dyslipidemia | Directeur/Membre du Conseil | - |
| Sociétés | Poste | Fin |
|---|---|---|
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Analyste en capital-investissement | 01/03/2024 |
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Private Equity Investor | 30/07/2019 |
| NOVARTIS AG | Corporate Officer/Principal | 01/12/2017 |
| ANNEXON, INC. | Directeur/Membre du Conseil | - |
| TSCAN THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Annexon, Inc.
 Annexon, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for neurodegenerative and autoimmune disorders | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
École Polytechnique Fédérale de Lausanne
 École Polytechnique Fédérale de Lausanne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Finance |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat dyslipidemia | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TScan Therapeutics, Inc.
 TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Mestag Therapeutics Ltd.
Mestag Therapeutics Ltd. Financial ConglomeratesFinance Provides investment services | Finance |
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Engages in research and development of transformative therapies for cardio metabolic diseases | Health Technology |
NewAmsterdam Pharma Co. NV
 NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
